Comprometimento cognitivo leve: rastreio cognitivo ou avaliação neuropsicológica? by DINIZ, Breno Satler et al.
Mild cognitive impairment: cognitive screening or 
neuropsychological assessment?
Comprometimento cognitivo leve: rastreio cognitivo 
ou avaliação neuropsicológica?
Abstract
Objective: To describe the neuropsychological profile of mild cognitive impairment subtypes (amnestic, non-amnestic and multiple-domain) 
of a clinical sample. We further address the diagnostic properties of the Mini-Mental State Examination and the Cambridge Cognitive 
Examination for the identification of the different mild cognitive impairment subtypes in clinical practice. Method: Cross-sectional clinical 
and neuropsychological evaluation of 249 elderly patients attending a memory clinic at a university hospital in Sao Paulo, Brazil. Results: 
The performance of patients with mild cognitive impairment was heterogeneous across the different subtests of the neuropsychological 
battery, with a trend towards an overall worse performance for amnestic (particularly multiple domain) mild cognitive impairment as 
compared to non-amnestic subtypes. Screening tests for dementia (Mini-Mental State Examination and Cambridge Cognitive Examination) 
adequately discriminated cases of mild Alzheimer’s disease from controls, but they were not accurate to discriminate patients with mild 
cognitive impairment (all subtypes) from control subjects. Conclusions: The discrimination of mild cognitive impairment subtypes was 
possible only with the aid of a comprehensive neuropsychological assessment. It is necessary to develop new strategies for mild cognitive 
impairment screening in clinical practice.
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Resumo 
Objetivo: Descrever o perfil neuropsicológico dos subtipos de comprometimento cognitivo leve, amnéstico, não-amnéstico e múlti-
plos domínios, de uma amostra clínica. Além disto, avaliou-se as propriedades diagnósticas do Mini-exame do Estado Mental e do 
Cambridge Cognitive Examination na identificação dos diferentes subtipos de comprometimento cognitivo leve na prática clínica. Método: 
Avaliação clínica e neuropsicológica transversal de 249 idosos em uma clínica de memória de um hospital universitário em São Paulo, 
Brasil. Resultados: Testes de rastreio para demência (Mini-exame do Estado Mental e Cambridge Cognitive Examination) identificam 
corretamente casos de doença de Alzheimer leve, mas não apresentam boa acurácia para diferenciar os diversos subtipos de comprome-
timento cognitivo leve. A performance dos sujeitos portadores de comprometimento cognitivo leve foi heterogênea nos diferentes testes 
da bateria neuropsicológica, com uma tendência a uma pior performance global nos pacientes com o subtipo amnéstico (especialmente 
os com envolvimento de múltiplos domínios cognitivos) em relação ao comprometimento cognitivo leve não-amnéstico. Conclusões: A 
discriminação dos diferentes subtipos de comprometimento cognitivo leve foi possível somente a partir de uma avaliação neuropsicológica 
detalhada. Desta maneira, é necessário o desenvolvimento de novas estratégias de rastreio para esta condição na prática clínica. 
Descritores: Transtornos cognitivos; Doença de Alzheimer; Testes neuropsicológicos; Diagnóstico; Demência
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Introduction
On clinical grounds, a current attempt to identify individuals at risk 
of developing Alzheimer’s disease (AD), or at least to characterize 
the cognitive manifestations of the disease at pre-clinical stages, 
relies on the diagnosis of mild cognitive impairment (MCI).1 The 
diagnostic criteria for MCI subsume the presence of subjective 
memory complaints, preferably corroborated by a close informant, 
and documented by an abnormal performance on cognitive tests, 
adjusted for age and education. These deficits must have no, or 
minimal, impact on global intellectual functioning and on the 
ability to perform activities of daily living, and the patient should 
not have evidence of dementia.2 A recent meta-analysis showed 
that patients with MCI evolve to dementia at rates of approximately 
10% per year.3 Boyle et al. showed that patients with MCI had a 6.7 
higher risk to progress to dementia.4 Such estimates are supported 
by other studies on early predictors of dementia.5,6 Nevertheless, 
these estimates show a great variability, from 5 to 40% per year,3
according to the setting where the studies were carried out (clinical 
versus population-based studies). 
Although the original diagnostic criteria for MCI emphasized 
the importance of memory impairment, more recently the MCI 
classification was expanded to encompass other cognitive domains, 
such as executive functioning and language, allowing the diagnosis 
of single and multiple-domain amnestic or non-amnestic MCI. In 
view of different neuropsychological profile, these subtypes were 
hypothesized to be associated with distinct outcomes.7 Whereas 
single-domain amnestic MCI may be a pre-dementia stage of AD, 
multiple-domain MCI may be a precursor of both AD or vascular 
dementia, and single domain non-amnestic MCI may be found in the 
prodromal phases of frontotemporal dementia, vascular dementia, 
dementia with Lewy bodies, or even depressive disorders.8
There are many unclear points with respect to the prognostic 
relevance of the MCI concept. Despite the evidence that poses MCI 
patients at a higher risk for converting to dementia, it is noteworthy 
that the current diagnostic criteria still yield a too heterogeneous 
group. Many of the patients fulfilling MCI criteria will remain stable or 
even resume normal cognitive functioning on follow-up.9,10 In such 
cases, there is no additional risk for dementia given the diagnosis 
of MCI.11 In addition, recent long-term, longitudinal studies failed 
to demonstrate that the classification according to MCI subtypes at 
baseline predicted distinct dementia outcomes.12,13 There are many 
potential reasons to explain such discrepant results in the literature, 
such as the unclear definition and quantification of cognitive 
“impairment” and of “minor” deficits in activities of daily living, the 
lack of standardized assessment tools across the various analyses, 
and different diagnostic conceptualization of the MCI diagnostic 
criteria.14,15 The development of biomarker technology, including 
CSF AE42 and Tau levels,16 and in vivo amyloid-E imaging with 
Positron Emission Tomography (PET),17 is likely to shed some light 
to this diagnostic impasse. 
Despite its clinical relevance, the diagnosis of MCI and its 
subtypes relies on comprehensive neuropsychological assessment. 
Thus, the identification of these subjects may be difficult in clinical 
practice, since this diagnostic procedure is not thoroughly available. 
In addition, few studies have addressed routinely used cognitive 
screening tests for dementia in the identification of MCI subjects. 
Ravaglia et al. showed that the combination of the Mini-Mental 
State Examination (MMSE) and the Clock Drawing Test (CDT) in 
the assessment of patients with suspected multiple-domain MCI 
increased the diagnostic sensitivity from the 40-50% range (either 
test alone, respectively) to 75%; however, in other MCI subtypes, 
the sensitivity of this intervention was much lower.18 Similarly, 
Tang-Way et al. found that the bedside screening test “Short Test of 
Mental Status” (STMS), which covers a broader range of cognitive 
abilities than the MMSE, is more accurate in the identification of 
MCI.19 However, the sensitivity and specificity of the tests used in 
the aforementioned studies were lower than 80%, which renders 
both tests unsuitable for screening purposes. On the other hand, 
Diniz et al. showed that the qualitative analysis of the performance 
of subjects in the subitems of the MMSE may help distinguish the 
MCI subtypes in clinical practice.20
The aim of the present study is to characterize the performance 
of MCI subtypes patients in a comprehensive battery as compared 
to the performance of healthy subjects and patients with AD. We 
further evaluate the diagnostic properties of cognitive screening tests 
routinely used in clinical practice (the MMSE and the Cambridge 
Cognitive Examination - CAMCOG) to discriminate the MCI subtypes 
from Alzheimer’s disease patients and controls subjects. 
Method
1. Patients
Two hundred and forty-nine patients (75% female) were assessed 
at the Memory Clinic of the Institute of Psychiatry, University of Sao 
Paulo, Brazil, between December 2001 and May 2007 (mean age: 
71.2 ± 7.9 years; mean educational level: 10.5 ± 5.9 years). 
In addition to the spontaneous demand for memory assessment, 
patients were also referred from other clinics due to suspected 
cognitive decline. In order to include cognitively unimpaired controls, 
relatives or acquaintances of patients, as well as volunteers from 
other sources, were invited to participate in the study. All subjects 
of this study signed their informed consent prior to enrolment. This 
study was approved by local Ethical Committee (process number 
1053/02) and was performed in accordance with the Helsinki 
Declaration.
2. Clinical and neuropsychological assessment
Patients and controls were examined by an expert multidisciplinary 
team, including geriatric psychiatrists, neurologists, geriatricians and 
neuropsychologists. Mental state examination was performed with 
the Brazilian version of the Cambridge Examination for Mental 
Disorders of the Elderly (CAMDEX) semi-structured interview,21,22
which yields scores for the CAMCOG, the Abbreviated Mental Test 
(AMT),23 the MMSE,24 and the Hachinski Ischemic Score, which 
assesses vascular pathology of the brain.25 The Clock Drawing Test, 
which is part of the CAMCOG schedule, was additionally scored 
accordingly to Sunderland’s guidelines.26 The 21-item Hamilton 
Depression Scale (HAM-D)27 was administered to rule out depressive 
symptomatology.
Trained neuropsychologists administered neuropsychological 
examinations to all study participants. The neuropsychological battery 
included tests for episodic memory: the Rivermead Behavioural 
Memory Test (RBMT),28,29 and the Fuld Object-Memory Evaluation 
(FOME), memory subscale of the Short Cognitive Test (SKT);30-32
language: verbal fluency (category: fruit); attention and psychomotor 
speedy: Trail Making Test A (TMT A), and attention subscale of the 
SKT; executive function: Trail Making Test B (TMT B);33 pre-morbid 
IQ: Wechsler Adult Intelligence Scale-Revised (WAIS-R) Vocabulary 
and Block Design tests.34 Evidence of functional decline was based 
on the scores of the Informant Questionnaire on Cognitive Decline in 
the Elderly (IQCODE),35 and on all available evidence of difficulties in 
the performance of basic and instrumental activities of daily living, 
as reported by a close relative or caregiver, and on the patient’s self-
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report. The neuropsychological evaluation was the “gold standard” 
for the distinction of the present cognitive status, i.e. dementia vs. 
MCI vs. cognitively unimpaired subjects. 
Laboratory tests were carried out for every patient to rule out 
potentially reversible causes of cognitive impairment, including: 
thyroid function, complete blood count, blood chemistry, folic 
acid and vitamin B12, blood lipid profile, and syphilis tests. 
Neuroimaging studies (CT scans or MRI) were completed according 
to clinical judgment. 
3. Diagnosis
Consensus diagnosis was reached at expert multidisciplinary 
meetings, taking into account clinical, neuropsychological, 
laboratorial, and neuroimaging data. Alzheimer’s disease was 
diagnosed according to the NINCDS-ADRDA criteria.36 The MCI 
diagnosis was made according to the following criteria: 1) subjective 
cognitive complain, preferably corroborated by an informant; 2) 
objective impairment in the performance on the cognitive tests of 
the assessment battery, but not severe enough to reach dementia 
diagnosis; 3) preserved global intellectual function; 4) preserved or 
minimal impairments in activities of daily living 5) not demented. 
MCI patients were further allocated into three different subcategories, 
according to the pattern of impairment on neuropsychological 
evaluation: a) amnestic (aMCI), if the evidence of impairment 
resulted from abnormal performance in memory tests only (e.g.: 
RBMT and/or FOME); b) non-amnestic (naMCI) in the presence 
of impairment in any single cognitive domain but memory; and 
c) multiple domain (mdMCI), if there was objective impairment 
in two or more cognitive domains including memory. Subjects 
without evidence of cognitive impairment were included in the 
control group. 
4. Statistical analysis
We performed Pearson’s Chi-square analysis to assess for 
differences in the distribution of gender among different diagnostic 
groups. Kolmogorov-Smirnov tests were done to assess for the 
normality of the distribution for each continuous variable. As these 
analyses showed that all variables had normal or near-normal 
distribution, we decided to carry out parametric statistical tests for 
all analyses. We carried out univariate analysis of variance (ANOVA) 
to assess mean differences for sociodemographic data, clinical 
variables, and scores on cognitive and neuropsychological tests 
among the diagnostic groups. If differences on sociodemographic 
or clinical variables known to influence cognitive performance 
were statistically significant among diagnostic groups in univariate 
analysis, we carried out multivariate analyses to control for the 
influence of these potential confounding variables on the scores 
of cognitive and neuropsychological tests. In addition, we carried 
out Bonferroni analyses for multiple comparisons to address mean 
differences in the scores of cognitive and neuropsychological tests 
between each diagnostic group. Receive Operator Characteristics 
(ROC) analyses were done to compare the diagnostic performance 
of the MMSE and the CAMCOG to identify MCI subtype cases in 
comparison to the gold standard neuropsychological evaluation. 
As the mean age of all diagnostic groups was higher than 8 years 
of schooling, we decided not to stratify the patients into different 
educational stratum to increase statistical power. All statistical 
analyses were performed using SPSS v14.0 for Windows (SPSS 
Inc., Chicago, IL) and A was set at 5%. 
Results
Table 1 illustrates sociodemographic characteristics of patients 
according to diagnostic groups. Seventy-three patients had mild to 
moderate AD (29%), 51 had multiple domains MCI (21%), 25 had 
amnestic MCI (10%), 11 had non-amnestic MCI (5%). Eighty-nine 
subjects were regarded cognitively unimpaired (controls, 35%). 
There was no difference in the distribution of diagnosis between 
genders. Univariate analysis of variance did not show statistical 
difference in the scores of HAM-D 21 (F 1.42, d.f. (4,244), 
p = 0.227). On the other hand, patients with AD were older, less 
educated, and had higher scores on the HIS than MCI and controls 
(Table 1 and 2). 
Multivariate analyses with diagnosis as the independent variable, 
and age, educational level, and the scores on the HIS as covariates 
to control for their confounding effect on the scores of clinical 
and neuropsychological tests showed that AD patients had worse 
performance in all cognitive tests as compared to MCI and controls. 
MCI patients (all subtypes) and normal controls had a similar overall 
performance on screening tests for dementia, such as the MMSE 
and the CDT. Patients with either amnestic- or non-amnestic MCI, 
but not with multiple-domain MCI, achieved similar mean scores 
on the CAMCOG test as compared to controls (Table 2).
In comparison to controls, patients with single-domain non-
amnestic MCI had mostly evidence of executive dysfunction, as 
depicted by the worse scores on the Trail B test. Multiple-domain 
MCI patients had, in addition to the memory impairment, significant 
deficits in praxis and executive functions. Interestingly, these patients 
had a performance somewhat similar to that of AD patients, at least 
in some of the cognitive tests in this battery (e.g., the Trail B and 
WAIS-R block design test), but had, by definition, no evidence of 
significant functional impairment (Table 2). Figure 1 shows the ROC 
analysis showing the best cutoff point, with its respective sensitivity 
and specificity, and Area under the Curve (AUC), for the MMSE and 
the CAMCOG according to each diagnostic category versus controls. 
Our results showed that the MMSE had poor diagnostic performance 
to discriminate between all MCI subtypes from controls. On the other 
hand, the CAMCOG showed a slightly better discriminative power 
to identify the MCI subtypes from controls, especially the multiple-
domain MCI (sensitivity, 85%; specificity, 75%). Both the MMSE 
and the CAMCOG had good diagnostic performance to discriminate 
between Alzheimer’s disease patients and control subjects. 
Discussion
The most common MCI subtype in this cohort was multiple-
domain amnestic MCI, corresponding to approximately two thirds 
of the MCI patients. Single-domain amnestic MCI occurred in 
Table 1 – Sociodemographic variables according to diagnosis
Controls Amnestic MCI Non-amnestic MCI Multiple-domain MCI AD p 
N (M/W) 89 (21/68) 25 (10/15) 11 (1/10) 51 (10/41) 73 (22/51) 0.184
Age (years)* 67.8 ± 6.1 72.3 ± 6.6 67.8 ± 4.8 70.2 ± 6.5 75.80 ± 7.9 < 0.001
Educational attainment (years) * 13.4 ± 5.8 10.8 ± 5.2 9.63 ± 6.6 8.5 ± 4.4 8.1 ± 5.4 < 0.001
* mean ± standard deviation. M: Men; W: Women; MCI: Mild Cognitive Impairment; AD: Alzheimer’s disease
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approximately 25% of the subjects, and non-amnestic MCI was 
the least frequent diagnosis. These results are in accordance with 
recent population and clinical studies.37
We showed that commonly used test for clinical assessment of 
dementia, i.e. the MMSE and the CAMCOG, had moderate accuracy 
for the identification of MCI subtypes in comparison to controls, 
as shown by the ROC analysis. These results were somewhat 
expected since these instruments were designed for the diagnosis 
of full-blown dementia syndromes, and, thus, show a ceiling effect 
when assessing subjects with less severe cognitive impairment, 
such as MCI.37 However, the CAMCOG displayed a better diagnostic 
performance profile in the identification of multiple-domain MCI 
patients than for the other subtypes. These results are in line with 
those reported by Ravaglia et al.18 As currently used cognitive 
screening tools do not have a high accuracy in the identification 
of most MCI patients, the development of cognitive screening tests 
primarily designed for the discrimination of such cases, e.g.: the 
Montreal Cognitive Assessment (MoCA), might help to overcome this 
issue.38 Hence, in the current practice, the identification of MCI (and 
its subtypes) still relies upon a comprehensive neuropsychological 
evaluation. The cutoff values reported herein should be viewed 
with caution, since these patients were assessed in a tertiary 
clinical memory and their educational background may not reflect 
the educational background of most Brazilian older individuals. 
Therefore, these results should be replicated in other clinical settings 
and populations. 
In the current sample, the amnestic MCI subjects had a global 
cognitive performance (as measured by the CAMCOG) worse than 
non-amnestic MCI did. This may be due in part to the fact that 
such memory impairment may result from milder disturbances 
on other cognitive domains. In addition, single domain (either 
amnestic or non-amnestic) MCI subjects had a better global cognitive 
performance than multiple-domain MCI subjects did. In the latter 
group, the performance on memory and executive function tasks 
was worse than of the single domain counterparts. 
The abnormal performance of multiple-domain MCI patients in 
certain tests, such as the WAIS-R block design and Trail B, was 
comparable to that of mild AD patients. This result may suggest that, 
as the cognitive deficits spread to more than one cognitive domain, 
particularly affecting executive functions, there is a progressive 
deterioration of global cognitive performance towards the clinical 
threshold of dementia, thus indicating that at least a subset of MCI 
patients may progress from aMCI to mdMCI prior to the conversion 
to AD. Additionally, aMCI patients (either single or multiple-domain) 
had a worse performance on the RBMT, along with a relatively 
preserved performance on the FOME. This result may be due to 
the different ability of these two tests to identify memory deficits 
in MCI patients, because the RBMT assesses different memory 
subsystems, such as prospective memory, episodic memory, visual 
and verbal memory, whereas, the FOME assesses only visual 
episodic memory, or perhaps, the two tests are differently affected 
by the education bias. 
Taken together, the current results on the performance of mdMCI 
and aMCI on distinct neuropsychological tests reinforce a recent 
debate raised in the literature regarding the usefulness of MCI 
concept.14 Although there seems to be a continuum between 
Table 2 - Scores on the cognitive screening tests, neuropsychological tests, the HAM-D 21, and the HIS from the clinical and 
neuropsychological battery according to diagnosis
Control Amnestic 
MCI
Non-amnestic MCI Multiple-domain MCI AD F P 
Cognitive screening tests
MMSE* 28.2 ± 1.8 26.40 ± 3.0 27.7 ± 1.8 26.5 ± 2.4 19.9 ± 4.7 48.4 <0 .001
CAMCOG& 96.4 ± 5.5 90.1 ± 8.4 91.3 ± 5.3 86.6 ± 8.4 65.9 ± 15.3 60.2 < 0.001
IQCODE* 3.15 ± 0.15 3.32 ± 0,37 3.25 ± 0.16 3.34 ± 0.37 3.81 ± 0.51 34.9 < 0.001 
CDT* 8.9 ± 1.8 8.6 ± 1.4 6.6 ± 2.5 7.5 ± 1.9 5.3 ± 2.7 18.0 < 0.001
AMT* 9.5 ± 0.8 9.0 ± 1.0 9.3 ± 1.1 9.0 ± 0.9 6.6 ± 2.1 29.1 < 0.001
HIS# 0.9 ± 1.6 0.9 ± 1.4 1.0 ± .8 1.3 ± 1.3 2.1 ± 1.88 6.6 < 0.001
HAM-D 21# 1.3 ± 2.4 2.2 ± 2.7 0.8 ± 1.4 1.5 ± 2.1 1.9 ± 2.4 1.4 0.227
Neuropsychological tests
RBMT screening score† 10.3 ± 1.7 7.1 ± 1.5‡ 9.7 ± 2.0 7.2 ± 2.0† 2.5 ± 2.2 100.3 < 0.001
- Profile score† 21.7 ± 2.5 17.4 ± 2.3‡ 21.0 ± 2.2 16.7 ± 3.6 6.7 ± 4.6 125.7 < 0.001
FOME total recall*            44.0 ± 3.1 41.1 ± 5.7 42.5 ± 2.7 38.3 ± 6.4 20.9 ± 9.6 92.6 < 0.001
- Delayed recall*         9.3 ± 0.8 8.7 ± 1.2 8.2 ± 1.1 8.4 ± 1.5 3.4 ± 2.5 105.9 < 0.001
Verbal fluency* 14.6 ± 3.1 12.6 ± 3,5 13.9 ± 3.0 11.4 ± 2.5 9.9 ± 2.6 16.2 < 0.001 
Trail A (seconds)‡ 47.8 ± 17.3 61.6 ± 25.6 78.7 ± 24.4 92.4 ± 47.3 118.7 ± 51.2 19.6 < 0.001
Trail B (seconds) ‡ 114.6 ± 50.3 135.7 ± 54.7 227.5 ± 83.1 223.2 ± 64.3 274.6 ± 56.4 53.3 < 0.001
SKT total scaled score& 2.3 ± 2.7 3.3 ± 2.8 3.1 ± 2.5 5.4 ± 3.4 11.4 ± 3.9 55.7 < 0.001
WAIS-R vocabulary†† 56.0 ± 9.3 45.1 ± 10.9 49.3 ± 12.0 41.5 ± 11.4 39.3 ± 10.2 14.6 < 0.001
- Block design‡ 22.6 ± 7.8 21.6 ± 6.5 18.5 ± 6.0 15.4 ± 6.9 10.6 ± 6.6 15.7 < 0.001
Scores displayed as unadjusted mean ± standard deviation.
Bonferroni analysis for multiple comparisons:
* controls = MCI subtypes > AD; & controls = aMCI, naMCI > mdMCI > AD; †  controls = naMCI >aMCI > mdMCI> AD; ‡ controls = aMCI, naMCI > mdMCI = AD; 
††controls > aMCI > naMCI, mdMCI = AD.
MMSE: Mini-Mental State Examination; CAMCOG: Cambridge Cognitive Examination; AMT: Abbreviated Mental Test; CDT: Clock Drawing Test; IQCODE: 
Informant Questionnaire of Cognitive Decline in the Elderly; HIS: Hachinski Ischemic Score; HAM-D 21: Hamilton Depression Scale 21 items. RBMT: Rivermead 
Behavioural Memory Test; FOME: Fuld Object-Memory Evaluation; SKT: Short Cognitive Test; WAIS-R: Wechsler Adult Intelligence Scale-Revised; aMCI: Amnestic 
Mild Cognitive Impairment; naMCI: Non-Amnestic Mild Cognitive Impairment; mdMCI: Multiple-Domain Mild Cognitive Impairment; AD: Alzheimer’s Disease. 
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normal aging, MCI and dementia on a subgroup of patients, the 
current diagnostic criteria for MCI still yields a highly heterogeneous 
group, which jeopardizes its prognostic relevance. This may be a 
result from the lack of a clear definition of normal vs. pathological 
cognitive impairment or decline. In addition, in view of the intra-
group heterogeneity of performance on neuropsychological tests that 
assess the same cognitive domains (e.g., the performance on the 
RBMT different from the FOME), we believe that the establishment 
of a concise but comprehensive cognitive assessment battery 
would be welcome to standardize the assessment for MCI across 
different populations. Follow-up studies of this cohort are underway 
in order to confirm present results, the stability and validity of the 
MCI concept, and the conversion rates and prognostic value of the 
MCI patients. 
In conclusion, the discrimination of MCI from normal aging is a 
difficult task in clinical settings, and requires an extensive cognitive 
assessment. A more accurate characterization of cognitive changes 
in normal and pathological aging, a more precise conceptualization 
of MCI, and definition of core neuropsychological tests in the 
assessment of patients with suspected cognitive decline is needed 
in order to clarify these important aspects of the transition from 
healthy aging to dementia.
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